How to appeal a denied claim for formulary exclusion.
A formulary-exclusion denial — your prescription or service is excluded from the carrier’s published formulary rather than denied on the underlying clinical merit — is the third most common shape of denial-reason we see, alongside the step-therapy (fail-first) and medical-necessity (coding-bundle) denials. The appeal pathways are different: a formulary exclusion is reversed by a formulary exception, with the cited framework split between the federal ACA Nondiscrimination obligation at 45 C.F.R. § 147.136 (binding on ACA marketplace plans), state-specific formulary-exception pathways (California Knox-Keene under Cal. Health & Safety Code § 1368; New York DFS protocol override under N.Y. Ins. Law § 4905; Illinois 215 ILCS 125/5-6 psychiatric carve-out; Florida and Texas analogous channels), and the federal ERISA § 503 claims-procedure rule at 29 C.F.R. § 2560.503-1 for self-funded employer plans operating in every state. The federal Medicare Part D formulary-exception framework at 42 C.F.R. § 423.578(c) supplies a parallel channel for Medicare Advantage / Part D plans. The well-built formulary-exclusion appeal letter cites the controlling framework, the documented clinical evidence justifying the off-formulary medication, and the published formulary-exception procedure that applies to the carrier.
01 · What this denial looks like
A formulary-exclusion denial — and the formulary-exception framework that applies to it.
A formulary-exclusion denial cites the published formulary as the basis for the denial — typically “drug not on formulary,” “non-preferred drug,” “tier-3 or tier-4 exclusion,” “Rx requires prior authorization and criteria not met,” or “non-formulary exception not established.” The dispute is the same shape as a step-therapy (fail-first) denial: the prescribed medication carries a clinical indication supported by the member’s chart evidence, but the carrier’s published formulary substitutes a preferred step or excludes the prescribed drug. The federal ACA Nondiscrimination rule at 45 C.F.R. § 147.136 constrains substantive clinical criteria for ACA marketplace plans, and the four-month external-review window at (d) attaches on the second-stage level. Where a state has a specific formulary-exception channel — California Knox-Keene / DMHC, New York DFS protocol override under § 4905, Illinois 215 ILCS 125/5-6 psychiatric carve-out, Florida OIR, Texas TDI — that state-specific channel runs in parallel with the federal ACA window and the most protective of the two carries the day.
For non-psychiatric drugs in fully-insured FL / TX / CA / NY / IL plans, the formulary-exception request follows the carrier-published pharmacy benefit plan document and the parallel state adverse-determination framework. For psychiatric and substance-use prescriptions in Illinois (215 ILCS 125/5-6) and increasingly in the other states’ analogous provisions, the carve-out supplies a state-specific ground to challenge the carrier’s fail-first or non-formulary-grounds decision directly under state law — and the appeal letter cites it as the framework that controls. For Medicare Part D plans, the formulary-exception framework at 42 C.F.R. § 423.578(c) supplies a 72-hour expedited exception for ongoing-care cases — a Medicare-specific fast-path that does not exist on commercial fully-insured plans. For self-funded ERISA plans in every state, the federal ERISA § 503 procedure at 29 C.F.R. § 2560.503-1 governs, with the 180-day internal-appeal window from the ABD.
A well-built formulary-exclusion appeal letter cites the controlling federal or state framework (45 C.F.R. § 147.136 for ACA plans; 42 C.F.R. § 423.578(c) for Medicare Part D; the carrier-published PBM formulary-exception procedure for non-psychiatric drugs; 215 ILCS 125/5-6 or the parallel state carve-out for psychiatric drugs in IL; the four-month ACA / four-month state external-review channel on the second-stage level), attaches the documented clinical evidence justifying the off-formulary medication (chart notes, prior failure on preferred step, contraindication, allergy or intolerance), and frames the request as a formulary-exception request under the cited framework. The letter branches on whether the denial is at first-stage internal appeal (carrier-published PBM formulary-exception procedure plus the state adverse-determination framework), or at the second-stage external-review level (45 C.F.R. § 147.136(d), 50 Ill. Adm. Code 4525.30 for IL, 28 Tex. Admin. Code § 3.1010 for TX, § 627.646 for FL, 1370.4 for CA, § 4914 for NY).
01 · The three counter-arguments
The formulary-exception counter-argument framework — three named grounds the letter preserves.
01
Documented prior failure on preferred step
The member has tried the carrier’s preferred formulary step agent at a clinically adequate dose for a clinically adequate duration, and the therapeutic outcome was inadequate, intolerable, or contraindicated. The clinical record documents the trial outcomes — symptom control, side effect profile, discontinuation date — and supports the case for moving to the prescribed off-formulary agent under the carrier’s published formulary-exception procedure, the federal ACA Nondiscrimination framework at 45 C.F.R. § 147.136, or the controlling state-specific formulary channel.
02
Contraindication or allergy on the preferred step
The carrier’s preferred step agent carries a documented contraindication or allergy tied to the member’s clinical profile — comorbidity, pregnancy, organ impairment, drug interaction, or immunologic response. The clinical record documents the contraindication, and the appeal cites the off-formulary agent as the clinically appropriate substitute. The appeal letter requests the formulary exception under the carrier’s published formulary-exception procedure plus the controlling federal or state framework.
03
Clinical guideline or specialty society standard
The published clinical guideline or specialty society standard of care for the member’s diagnosis specifies the off-formulary medication as the first-line treatment, and the carrier’s published formulary substitutes a generic preferred step that contradicts the guideline. The appeal attaches the cited clinical guideline (NCCN, IDSA, APA, AHA, or the relevant specialty-society standard), frames the conflict as a clinical-criteria defect, and requests the formulary exception plus the four-month external-review window on the second-stage level (45 C.F.R. § 147.136(d)).
01 · State-specific formulary channels
Three jurisdictions with a state-specific formulary channel on the formulary-exception letter.
01
Illinois · 215 ILCS 125/5-6 psychiatric carve-out
IL psychiatric
The 2023 Illinois reform at 215 ILCS 125/5-6 carved out step-therapy-protocol exceptions for psychiatric and substance-use prescriptions — and the rationale extends to formulary exclusion for the prescribed drug class. For psychiatric and substance-use prescriptions, the 215 ILCS 125/5-6 carve-out supplies a state-specific ground to challenge the carrier’s fail-first or non-formulary-grounds decision directly under Illinois law — and the Illinois DOI complaint pathway at 1-877-527-9431 (insurance.illinois.gov) plus 50 Ill. Adm. Code 4525.30 routes the member to the 30-day external review (IRO). The appeal letter cites 215 ILCS 125/5-6 directly to put the carve-out ground on the record.
02
California · Knox-Keene §1368 formulary-exception framework
CA Knox-Keene
California Knox-Keene licensees (Kaiser Permanente, Health Net, Blue Shield of California, Anthem Blue Cross) are bound by Cal. Health & Safety Code § 1368 on enrollee-facing utilization-review and the carrier-published formulary. The Knox-Keene § 1368 framework layers on top of the federal ACA Nondiscrimination rule at 45 C.F.R. § 147.136, with the DMHC Help Center 1-888-466-2219 (dmhc.ca.gov) routing the enrollee to the 180-day IMR window. The appeal cites both the federal ACA framework and the Knox-Keene / DMHC complaint pathway, and reserves the IMR if the carrier refuses to apply the formulary exception.
03
New York · N.Y. Ins. Law § 4905 protocol-override pathway
NY override
New York fully-insured plans are bound by the NYDFS protocol-override pathway for formulary-exception requests, codified at N.Y. Ins. Law § 4905 with the 24-hour NYDFS expedited external appeal response for ongoing-care cases. The 11 NYCRR 71.4 binding Approved Review Organization (ARO) procedure applies to NY formulary-exception disputes that escalate to external appeal, and the NYDFS Consumer Hotline 1-800-342-3736 routes the member to the external-appeal packet. The appeal cites both § 4905 and the binding ARO procedure to put the protocol-override ground on the record.
02 · Frequently asked
The formulary-exception, ERISA, and state frameworks that apply on a formulary-exclusion denial.
Cited: 45 C.F.R. § 147.136 (ACA Nondiscrimination) · 42 C.F.R. § 423.578(c) (Medicare Part D formulary exception) · 29 C.F.R. § 2560.503-1 (ERISA § 503) · Cal. Health & Safety Code § 1368 (California Knox-Keene) · 215 ILCS 125/5-6 (Illinois psychiatric step-therapy carve-out).
A formulary-exclusion denial cites the published formulary as the basis for the denial — typically “drug not on formulary,” “non-preferred drug,” “tier-3 or tier-4 exclusion,” “Rx requires prior authorization and criteria not met,” or “non-formulary exception not established.” The dispute is the same shape as a step-therapy (fail-first) denial: the prescribed medication carries a clinical indication supported by the member’s chart evidence, but the carrier’s published formulary substitutes a preferred step or excludes the prescribed drug. The federal ACA Nondiscrimination rule at 45 C.F.R. § 147.136 constrains substantive clinical criteria for ACA marketplace plans, and the four-month external-review window at (d) attaches on the second-stage level. Where a state has a specific formulary-exception channel — California Knox-Keene / DMHC, New York DFS protocol override under § 4905, Illinois 215 ILCS 125/5-6 psychiatric carve-out, Florida OIR, Texas TDI — that state-specific channel runs in parallel with the federal ACA window and the most protective of the two carries the day.
For non-psychiatric drugs in fully-insured FL / TX / CA / NY / IL plans, the formulary-exception request follows the carrier-published pharmacy benefit plan document and the parallel state adverse-determination framework. For psychiatric and substance-use prescriptions in Illinois (215 ILCS 125/5-6) and increasingly in the other states’ analogous provisions, the carve-out supplies a state-specific ground to challenge the carrier’s fail-first or non-formulary-grounds decision directly under state law — and the appeal letter cites it as the framework that controls. For Medicare Part D plans, the formulary-exception framework at 42 C.F.R. § 423.578(c) supplies a 72-hour expedited exception for ongoing-care cases — a Medicare-specific fast-path that does not exist on commercial fully-insured plans. For self-funded ERISA plans in every state, the federal ERISA § 503 procedure at 29 C.F.R. § 2560.503-1 governs, with the 180-day internal-appeal window from the ABD.
02 · Frequently asked
Cited: 45 C.F.R. § 147.136 (ACA Nondiscrimination) · 42 C.F.R. § 423.578(c) (Medicare Part D formulary exception) · 29 C.F.R. § 2560.503-1 (ERISA § 503) · Cal. Health & Safety Code § 1368 (California Knox-Keene) · 215 ILCS 125/5-6 (Illinois psychiatric step-therapy carve-out).
Browse by state
Pick your state to see the appeal framework that applies.
Every state has a different agency, timeline, and binding external-review channel — start with yours.
03 · Submit the formulary exclusion
The same formulary exclusion — defended with the formulary-exception framework that applies to the carrier.
Upload the EOB or formulary denial letter, answer the four short intake questions, and Denvow picks the federal ACA Nondiscrimination rule at 45 C.F.R. § 147.136 for ACA marketplace plans, the Medicare Part D formulary-exception framework at 42 C.F.R. § 423.578(c) for Medicare plans, the controlling state-specific channel (CA Knox-Keene § 1368 for Knox-Keene licensee plans; NY § 4905 protocol override for NY fully-insured; IL 215 ILCS 125/5-6 carve-out for psychiatric prescriptions in IL; FL § 627.646 IRO for OIR-regulated FL plans; TX 28 Tex. Admin. Code § 3.1010 for TDI-regulated TX plans), or the federal ERISA § 503 procedure at 29 C.F.R. § 2560.503-1 for self-funded employer plans — and the letter branches on whether you’re at the first-stage formulary-exception request or the four-month external-review / 72-hour Medicare-expedited window.
Already in the intake? Type the carrier-published drug name in the Intake Drug field on the form — the script templates the documented-prior-failure paragraph against the carrier’s published formulary tier. Answer the rest of the four questions and submit.
Other denial-reason pages
Denvow is template-and-tooling, not legal counsel. For denials that genuinely need litigation, an ERISA fiduciary complaint, or a state-court remedy, we recommend a licensed attorney in the relevant jurisdiction — and will say so when we see one.